LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY

被引：1
|
作者：
Platzbecker, U. [1 ]
Germing, U. [2 ]
Giagounidis, A. [3 ]
Goetze, K. [4 ]
Kiewe, P. [5 ]
Mayer, K. [6 ]
Ottmann, O. [7 ]
Radsak, M. [8 ]
Wolff, T. [9 ]
Haase, D. [10 ]
Hankin, M. [11 ]
Wilson, D. [11 ]
Zhang, X. [11 ]
Laadem, A. [12 ]
Sherman, M. [11 ]
Attie, K. [11 ]
机构：
[1] Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Dresden, Germany
[2] Univ Klinikum Dusseldorf, Klin Hamatol Onkol & Klin Immunol, Dusseldorf, Germany
[3] Marien Hosp, Klin Onkol Hamatol & Palliat Med, Dusseldorf, Germany
[4] Tech Univ Munich, Med Klin & Poliklin 3, D-80290 Munich, Germany
[5] Onkol Schwerpunkt Oskar Helene Heim, Med Versorgungszentrum, Berlin, Germany
[6] Univ Klinikum Bonn, Med Klin & Poliklin 3, Bonn, Germany
[7] Klinikum JW Goethe Univ, Med Klin Hamatol Onkol 2, Frankfurt, Germany
[8] Johannes Gutenberg Univ Mainz, Med Klin 3, Univ Med Ctr, D-55122 Mainz, Germany
[9] OncoRes Lerchenfeld UG, Hamatol Intern Onkol Palliat Med, Hamburg, Germany
[10] Univ Med Gottigen, Abt Hamatol & Onkol, Gottingen, Germany
[11] Acceleron Pharma, Med Res, Cambridge, MA USA
[12] Celgene Corp, Med Res, Summit, NJ USA
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30054-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
53
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [31] Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
    Valcarcel, David
    Sanz, Guillermo
    Ortega, Margarita
    Nomdedeu, Benet
    Luno, Elisa
    Diez-Campelo, Maria
    Teresa Ardanaz, Maria
    Pedro, Carmen
    Montoro, Julia
    Collado, Rosa
    Andreu, Rafa
    Marco, Victor
    Teresa Cedena, Maria
    de Paz, Raquel
    Tormo, Mar
    Xicoy, Blanca
    Ramos, Fernando
    Bargay, Joan
    Gonzalez, Bernardo
    Brunet, Salut
    Antonio Munoz, Juan
    Gomez, Valle
    Bailen, Alicia
    Sanchez, Joaquin
    Merchan, Brayan
    del Canizo, Consuelo
    Vallespi, Teresa
    [J]. LANCET HAEMATOLOGY, 2015, 2 (06): : E260 - E266
  • [32] Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Xiao, Lianchun
    Najla, Al Ali
    Mishra, Asmita
    Padron, Eric
    Lancet, Jeffrey E.
    Bryan, Jeffery
    Prescott, Hillary
    Steensma, David P.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    List, Alan
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    [J]. BLOOD, 2013, 122 (21)
  • [33] 5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program
    Musto, Luca Maurillo
    Spagnoli, Alessandra
    Gozzini, Antonella
    Rivellini, Flavia
    Tatarelli, Caterina
    Lunghi, Monia
    Fili, Carla
    Orciuolo, Enrico
    Ciuffreda, Lucia
    Vigna, Ernesto
    Della Cioppa, Paola
    Candoni, Anna
    Ferrero, Dario
    Palmieri, Salvatore
    Palumbo, Giuseppe
    Di Renzo, Nicola
    Oliva, Esther
    Sanpaolo, Grazia
    Pastore, Domenico
    Tonso, Anna
    Santagostino, Alberto
    Rocco, Stefano
    Villani, Oreste
    D'Auria, Fiorella
    D'Arco, Alfonso Maria
    Gaidano, Gianluca
    Galimberti, Sara
    Russo, Domenico
    Venditti, Adriano
    Aloe-Spiriti, Maria Antonietta
    Leone, Giuseppe
    Santini, Valeria
    [J]. BLOOD, 2008, 112 (11) : 926 - 927
  • [34] 5-AZACYTIDINE FOR THE TREATMENT OF LOW/INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 63 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM
    Musto, P.
    Maurillo, L.
    Spagnoli, A.
    Gozzini, A.
    Rivellini, F.
    Tatarelli, C.
    Lunghi, M.
    Fili, C.
    Orciuolo, E.
    Ciuffreda, L.
    Vigna, E.
    Della Cioppa, P.
    Ferrero, D.
    Palmieri, S.
    Palumbo, G.
    Di Renzo, N.
    Oliva, E.
    Sanpaolo, G.
    Pastore, D.
    Tonso, A.
    Santagostino, A.
    Villani, O.
    D'Auria, F.
    D'Arco, A.
    Gaidano, G.
    Galimberti, S.
    Russo, D.
    Venditti, A.
    Aloe-Spiriti, M. A.
    Leone, G.
    Santini, V.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 368 - 368
  • [35] Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial
    Garcia-Manero, Guillermo
    Yee, Karen W. L.
    Hernandez, Francisca
    Della Porta, Matteo Giovanni
    Paolini, Stefania
    Ahn, Seo-Yeon
    Santini, Valeria
    Fenaux, Pierre
    Suzuki, Takahiro
    Sekeres, Mikkael A.
    He, Jun
    Li, Jerry
    Barkalifa, Ronit
    Vigil, Carlos E.
    Prebet, Thomas
    de Menezes, Daniel Lopes
    Burnett, Joseph
    Komrokji, Rami S.
    Giagounidis, Aristoteles
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Luspatercept Reduces Red Blood Cell Transfusions (RBCT) in Patients with Lower-Risk Myelodysplastic Syndromes (LRMDS) Regardless of Baseline Transfusion Burden (TB) in the MEDALIST Study
    Platzbecker, Uwe
    Garcia-Manero, Guillermo
    Fenaux, Pierre
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Tang, Derek
    Ito, Rodrigo
    Fabre, Shannon
    Mantovani, Emily
    Zoffoli, Roberto
    Miteva, Dimana
    Hughes, Christina
    Khan, Wasiulla
    Komrokji, Rami S.
    Germing, Ulrich
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 142 - 142
  • [37] Arsenic trioxide in patients with myelodysplastic syndromes (MDS): Preliminary results of a phase II clinical study.
    List, AF
    Schiller, GJ
    Mason, J
    Douer, D
    Ellison, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 561S - 561S
  • [38] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. HAEMATOLOGICA, 2017, 102 : 484 - 484
  • [39] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. LEUKEMIA RESEARCH, 2017, 55 : S29 - S30
  • [40] Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study.
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Kiewe, Philipp M.
    Germing, Ulrich
    Gotze, Katharina S.
    Mayer, Karin
    Radsak, Markus
    Wolff, Thomas
    Chromik, Joerg
    Reynolds, Joseph
    Barron, Carolyn
    Rovaldi, Chris
    Suragani, Rajasekhar N. V. S.
    Zhang, Xiaosha
    Laadem, Abderrahmane
    Linde, Peter G.
    Sherman, Matthew L.
    Oelschlaegel, Uta
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345